应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02190 归创通桥-B
休市中 04-19 16:08:35
9.270
-0.210
-2.22%
最高
9.440
最低
9.260
成交量
3.60万
今开
9.340
昨收
9.480
日振幅
1.90%
总市值
30.81亿
流通市值
30.09亿
总股本
3.32亿
成交额
33.70万
换手率
0.01%
流通股本
3.25亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
归创通桥-B(02190)4月17日回购4000股
智通财经 · 04-17 20:12
归创通桥-B(02190)4月17日回购4000股
归创通桥-B(02190.HK)4月16日耗资93.3万港元回购10.4万股
港股那点事 · 04-16
归创通桥-B(02190.HK)4月16日耗资93.3万港元回购10.4万股
归创通桥-B(02190)4月16日斥资93.31万港元回购10.4万股
智通财经 · 04-16
归创通桥-B(02190)4月16日斥资93.31万港元回购10.4万股
归创通桥-B(02190)下跌5.31%,报9.1元/股
金融界 · 04-05
归创通桥-B(02190)下跌5.31%,报9.1元/股
归创通桥-B04月02日主力资金流出27万元 连续3日减仓
自选股智能写手 · 04-02
归创通桥-B04月02日主力资金流出27万元 连续3日减仓
归创通桥-B(02190)上涨5.06%,报10.18元/股
金融界 · 04-02
归创通桥-B(02190)上涨5.06%,报10.18元/股
归创通桥-B盘中异动 股价大涨5.06%报10.181港元
自选股智能写手 · 04-02
归创通桥-B盘中异动 股价大涨5.06%报10.181港元
2023全年业绩揭榜,集采大考下创新医疗器械企业表现几何?
格隆汇 · 04-02
2023全年业绩揭榜,集采大考下创新医疗器械企业表现几何?
归创通桥-B(02190):国家药监局批准通桥麒麟™血流导向装置上市
智通财经 · 03-25
归创通桥-B(02190):国家药监局批准通桥麒麟™血流导向装置上市
归创通桥2023年营业收入增长58%达到5.3亿元
证券日报 · 03-22
归创通桥2023年营业收入增长58%达到5.3亿元
归创通桥-B发布2023年度业绩 收入5.28亿元同比显著增长58%
新浪港股 · 03-22
归创通桥-B发布2023年度业绩 收入5.28亿元同比显著增长58%
《公司业绩》归创通桥(02190.HK)全年亏损收窄至7,873万人民币
阿斯达克财经 · 03-22
《公司业绩》归创通桥(02190.HK)全年亏损收窄至7,873万人民币
归创通桥-B(02190)发布年度业绩,收入5.28亿元 同比显著增长58%
智通财经网 · 03-21
归创通桥-B(02190)发布年度业绩,收入5.28亿元 同比显著增长58%
归创通桥(02190)2023年业绩亮眼:营业收入增长58%达到5.3亿元 实现经调整净利润口径下盈利
智通财经 · 03-21
归创通桥(02190)2023年业绩亮眼:营业收入增长58%达到5.3亿元 实现经调整净利润口径下盈利
归创通桥-B盘中异动 急速拉升7.69%
自选股智能写手 · 03-18
归创通桥-B盘中异动 急速拉升7.69%
归创通桥-B(02190)上涨5.05%,报10.2元/股
金融界 · 03-14
归创通桥-B(02190)上涨5.05%,报10.2元/股
归创通桥-B盘中异动 早盘股价大涨5.04%
自选股智能写手 · 03-14
归创通桥-B盘中异动 早盘股价大涨5.04%
归创通桥-B(02190)股价上升5.046%,现价港币$10.2
阿斯达克财经 · 03-14
归创通桥-B(02190)股价上升5.046%,现价港币$10.2
归创通桥-B(02190.HK)拟3月21日举行董事会会议批准全年业绩
格隆汇资讯 · 03-08
归创通桥-B(02190.HK)拟3月21日举行董事会会议批准全年业绩
加载更多
公司概况
公司名称:
归创通桥-B
所属市场:
SEHK
上市日期:
--
主营业务:
归创通桥医疗科技股份有限公司(原名:浙江归创医疗器械有限公司),是一家主要从事神经和外周血管介入医疗器械产品研发的中国公司。该公司主要产品包括蛟龙颅内取栓支架和Ultrafree药物洗脱PTA球囊扩张导管(Ultrafree DCB)。该公司产品销往国内外市场。
发行价格:
--
{"stockData":{"symbol":"02190","market":"HK","secType":"STK","nameCN":"归创通桥-B","latestPrice":9.27,"timestamp":1713514115031,"preClose":9.48,"halted":0,"volume":36000,"delay":0,"floatShares":324619744,"shares":332401001,"eps":-0.25870234,"marketStatus":"休市中","marketStatusCode":7,"change":-0.21,"latestTime":"04-19 16:08:35","open":9.34,"high":9.44,"low":9.26,"amount":336995,"amplitude":0.018987,"askPrice":9.27,"askSize":4500,"bidPrice":9.26,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-0.2587023252108936,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713749400000},"adr":0,"listingDate":1625414400000,"adjPreClose":9.48,"openAndCloseTimeList":[[1713490200000,1713499200000],[1713502800000,1713513600000]],"volumeRatio":0.18907563024217042,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02190","defaultTab":"news","newsList":[{"id":"2428329312","title":"归创通桥-B(02190)4月17日回购4000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2428329312","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428329312?lang=zh_cn&edition=full","pubTime":"2024-04-17 20:12","pubTimestamp":1713355977,"startTime":"0","endTime":"0","summary":"智通财经APP讯,归创通桥-B(02190)发布公告,于2024年4月17日,该公司斥资3.8万港元回购4000股,每股回购价为9.5港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1104114.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427216826","title":"归创通桥-B(02190.HK)4月16日耗资93.3万港元回购10.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427216826","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2427216826?lang=zh_cn&edition=full","pubTime":"2024-04-16 20:20","pubTimestamp":1713270015,"startTime":"0","endTime":"0","summary":"格隆汇4月16日丨归创通桥-B(02190.HK)公告,4月16日耗资93.3万港元回购10.4万股,每股价格为8.78-9.09港元。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-16/doc-inarzueu9453796.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-16/doc-inarzueu9453796.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2427882505","title":"归创通桥-B(02190)4月16日斥资93.31万港元回购10.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427882505","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427882505?lang=zh_cn&edition=full","pubTime":"2024-04-16 20:04","pubTimestamp":1713269048,"startTime":"0","endTime":"0","summary":"智通财经APP讯,归创通桥-B(02190)发布公告,于2024年4月16日,该公司斥资93.31万港元回购10.4万股,每股回购价为8.78-9.09港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103506.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425056233","title":"归创通桥-B(02190)下跌5.31%,报9.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425056233","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425056233?lang=zh_cn&edition=full","pubTime":"2024-04-05 10:31","pubTimestamp":1712284270,"startTime":"0","endTime":"0","summary":"4月5日,归创通桥-B(02190)盘中下跌5.31%,截至10:31,报9.1元/股,成交104.32万元。归创通桥医疗科技股份有限公司是中国神经和外周血管介入医疗器械市场的领导者,主要为中国及海外的医生和患者提供治疗及应对神经和外周血管疾病的先进医疗器械。公司的主要治疗领域包括急性缺血性脑卒中、颅内动脉瘤、颈动脉狭窄、外周动脉和静脉疾病以及透析相关疾病。截至2023年年报,归创通桥-B营业总收入5.28亿元、净利润-7873.4万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/05103140128815.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424306490","title":"归创通桥-B04月02日主力资金流出27万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2424306490","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424306490?lang=zh_cn&edition=full","pubTime":"2024-04-02 16:15","pubTimestamp":1712045714,"startTime":"0","endTime":"0","summary":"04月02日, 归创通桥-B股价涨2.99%,报收9.98元,成交金额502万元,换手率0.15%,振幅4.95%,量比1.70。归创通桥-B今日主力资金净流出27万元,连续3日净流出,上一交易日主力净流出24万元,今日环比增加12.50%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为75.00%,平均跌幅为1.10%。该股近5个交易日上涨3.42%,主力资金累计净流出90万元;近20日主力资金累计净流出211万元,其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040216152487d46971&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040216152487d46971&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424033430","title":"归创通桥-B(02190)上涨5.06%,报10.18元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424033430","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2424033430?lang=zh_cn&edition=full","pubTime":"2024-04-02 10:42","pubTimestamp":1712025750,"startTime":"0","endTime":"0","summary":"4月2日,归创通桥-B(02190)盘中上涨5.06%,截至10:42,报10.18元/股,成交132.19万元。归创通桥医疗科技股份有限公司是中国神经和外周血管介入医疗器械市场的领导者,主要为中国及海外的医生和患者提供治疗及应对神经和外周血管疾病的先进医疗器械。公司的主要治疗领域包括急性缺血性脑卒中、颅内动脉瘤、颈动脉狭窄、外周动脉和静脉疾病以及透析相关疾病。截至2023年年报,归创通桥-B营业总收入5.28亿元、净利润-7873.4万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/02104240089415.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424036641","title":"归创通桥-B盘中异动 股价大涨5.06%报10.181港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2424036641","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424036641?lang=zh_cn&edition=full","pubTime":"2024-04-02 10:42","pubTimestamp":1712025746,"startTime":"0","endTime":"0","summary":"2024年04月02日早盘10时42分,归创通桥-B股票出现波动,股价急速上涨5.06%。截至发稿,该股报10.181港元/股,成交量13.35万股,换手率0.04%,振幅4.95%。资金方面,该股资金流入94.021万港元,流出9.861万港元。归创通桥-B股票所在的医疗设备及用品行业中,整体跌幅为0.13%。其相关个股中,紫元元、春立医疗、爱康医疗涨幅较大,振幅较大的相关个股有微创医疗、健世科技-B、鹰瞳科技-B,振幅分别为14.31%、13.68%、11.89%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240402104227791e5a7d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240402104227791e5a7d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424084097","title":"2023全年业绩揭榜,集采大考下创新医疗器械企业表现几何?","url":"https://stock-news.laohu8.com/highlight/detail?id=2424084097","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2424084097?lang=zh_cn&edition=full","pubTime":"2024-04-02 09:51","pubTimestamp":1712022663,"startTime":"0","endTime":"0","summary":"创新医疗器械强者恒强","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/108.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/108.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/715171","is_publish_highlight":false,"gpt_icon":0},{"id":"2422560615","title":"归创通桥-B(02190):国家药监局批准通桥麒麟™血流导向装置上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2422560615","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422560615?lang=zh_cn&edition=full","pubTime":"2024-03-25 16:52","pubTimestamp":1711356749,"startTime":"0","endTime":"0","summary":"智通财经APP讯,归创通桥-B 发布公告,由集团自主研发的通桥麒麟血流导向装置已获国家药品监督管理局批准上市。截至本公告日期,公司已在中华人民共和国就合共41款产品获得国家药监局批准。我们预计2019年至2030年,使用血流导向装置治疗颅内动脉瘤的手术量复合增长率有望达到30%。通桥麒麟血流导向装置的获批上市,是公司致力于开发具有真正临床价值的差异化创新产品的最新成果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1091446.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421855004","title":"归创通桥2023年营业收入增长58%达到5.3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2421855004","media":"证券日报","top":-1,"share":"https://www.laohu8.com/m/news/2421855004?lang=zh_cn&edition=full","pubTime":"2024-03-22 14:22","pubTimestamp":1711088529,"startTime":"0","endTime":"0","summary":"本报记者徐一鸣见习记者金婉霞3月21日晚间,归创通桥发布2023年全年业绩公告。2023年,公司营业收入达5.3亿元,同比增长58.0%;毛利润同比增长52.4%达到3.8亿元;毛利率水平稳定在72.9%;2023年归创通桥实现经调整净利润703万元。年报显示,在国内市场,归创通桥成功把握集采带来的市场机遇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403223020980453.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421007240","title":"归创通桥-B发布2023年度业绩 收入5.28亿元同比显著增长58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421007240","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2421007240?lang=zh_cn&edition=full","pubTime":"2024-03-22 08:19","pubTimestamp":1711066759,"startTime":"0","endTime":"0","summary":"归创通桥-B(02190)发布截至2023年12月31日止年度业绩,该集团取得收入人民币5.28亿元(单位下同),同比增加58%;毛利3.85亿元,同比增加52.4%;公司权益持有人应占亏损7873.4万元,同比收窄30.66%;年内非《国际财务报告准则》经调整溢利703.3万元,去年同期则亏损2587.7万元;每股亏损0.24元。\n 公告称,收入的显著增长主要归因于神经血管和外周血管介入器械分部的高速销售增长。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-22/doc-inapcytw6484920.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-22/doc-inapcytw6484920.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2421076548","title":"《公司业绩》归创通桥(02190.HK)全年亏损收窄至7,873万人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2421076548","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2421076548?lang=zh_cn&edition=full","pubTime":"2024-03-22 03:28","pubTimestamp":1711049280,"startTime":"0","endTime":"0","summary":"归创通桥-B(02190.HK) 公布2023年止年度业绩,收入录得5.28亿人民币(下同),按年增加58%。亏损由上年度1.14亿元,收窄至7,873万元,每股亏损24分。不派末期息。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-21 16:25。)过往派息公布日期派息事项派息内容2023/08/23中期业绩无派息2023/03/29末期业绩无派息 2022/08/15中期业绩无派息 2022/03/15末期业绩无派息 AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220725164332772_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220725164332772_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1335727/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2421888049","title":"归创通桥-B(02190)发布年度业绩,收入5.28亿元 同比显著增长58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421888049","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2421888049?lang=zh_cn&edition=full","pubTime":"2024-03-21 21:59","pubTimestamp":1711029551,"startTime":"0","endTime":"0","summary":"智通财经APP讯,归创通桥-B 发布截至2023年12月31日止年度业绩,该集团取得收入人民币5.28亿元,同比增加58%;毛利3.85亿元,同比增加52.4%;公司权益持有人应占亏损7873.4万元,同比收窄30.66%;年内非《国际财务报告准则》经调整溢利703.3万元,去年同期则亏损2587.7万元;每股亏损0.24元。公告称,收入的显著增长主要归因于神经血管和外周血管介入器械分部的高速销售增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403212201168b51345f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403212201168b51345f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421804601","title":"归创通桥(02190)2023年业绩亮眼:营业收入增长58%达到5.3亿元 实现经调整净利润口径下盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2421804601","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2421804601?lang=zh_cn&edition=full","pubTime":"2024-03-21 21:54","pubTimestamp":1711029265,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,3月21日晚间,归创通桥医疗科技股份有限公司发布2023年全年业绩公告。报告期内,公司营业收入保持高速增长达到5.3亿元,同比增长58.0%;毛利润同比增长52.4%达到3.8亿元。伴随营收规模的扩大和运营效率的全面提升,2023年归创通桥实现经调整净利润703万元。同时,归创通桥持续扩大海外市场业务。2023年归创通桥海外地区收入达到1427万元人民币,同比增长83.1%。公司研发开支占营收比例由2022年的69.9%下降至49.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403212157168b5131ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403212157168b5131ab&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420460679","title":"归创通桥-B盘中异动 急速拉升7.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420460679","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420460679?lang=zh_cn&edition=full","pubTime":"2024-03-18 09:47","pubTimestamp":1710726432,"startTime":"0","endTime":"0","summary":"2024年03月18日早盘09时47分,归创通桥-B股票出现异动,股价急速拉升7.69%。截至发稿,该股报10.501港元/股,成交量1.6513万股,换手率0.01%,振幅9.54%。机构评级方面,在所有2家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。其相关个股中,归创通桥-B、康基医疗、君百延集团涨幅较大,振幅较大的相关个股有巨星医疗控股、归创通桥-B、康基医疗,振幅分别为11.76%、9.54%、5.93%。该公司产品销往国内外市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031809471387e79862&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031809471387e79862&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419569719","title":"归创通桥-B(02190)上涨5.05%,报10.2元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419569719","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419569719?lang=zh_cn&edition=full","pubTime":"2024-03-14 09:46","pubTimestamp":1710380776,"startTime":"0","endTime":"0","summary":"3月14日,归创通桥-B(02190)盘中上涨5.05%,截至09:46,报10.2元/股,成交100.36万元。归创通桥医疗科技股份有限公司是中国神经和外周血管介入医疗器械市场的领导者,主要为中国及海外的医生和患者提供治疗及应对神经和外周血管疾病的先进医疗器械。公司的主要治疗领域包括急性缺血性脑卒中、颅内动脉瘤、颈动脉狭窄、外周动脉和静脉疾病以及透析相关疾病。截至2023年中报,归创通桥-B营业总收入2.3亿元、净利润-3551.4万元。3月21日,归创通桥-B将披露2023财年年报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/14094639846561.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419690876","title":"归创通桥-B盘中异动 早盘股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2419690876","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419690876?lang=zh_cn&edition=full","pubTime":"2024-03-14 09:45","pubTimestamp":1710380759,"startTime":"0","endTime":"0","summary":"2024年03月14日早盘09时45分,归创通桥-B股票出现波动,股价急速拉升5.04%。截至发稿,该股报10.200港元/股,成交量9.55万股,换手率0.03%,振幅3.91%。归创通桥-B股票所在的医疗设备及用品行业中,整体涨幅为0.14%。其相关个股中,巨星医疗控股、普华和顺、百心安-B涨幅较大,振幅较大的相关个股有巨星医疗控股、诺辉健康、沛嘉医疗-B,振幅分别为17.39%、9.32%、7.63%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403140945597a4c8056&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403140945597a4c8056&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419769058","title":"归创通桥-B(02190)股价上升5.046%,现价港币$10.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2419769058","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2419769058?lang=zh_cn&edition=full","pubTime":"2024-03-14 09:45","pubTimestamp":1710380700,"startTime":"0","endTime":"0","summary":"[上升股]归创通桥-B(02190) 股价在上午09:45比前收市价上升5.046%,现股价为港币$10.2。至目前为止,今日最高价为$10.2,而最低价为$9.82。总成交量为9.45万股,总成交金额为港币$94.764万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR240314553/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2417084297","title":"归创通桥-B(02190.HK)拟3月21日举行董事会会议批准全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2417084297","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2417084297?lang=zh_cn&edition=full","pubTime":"2024-03-08 17:02","pubTimestamp":1709888529,"startTime":"0","endTime":"0","summary":"格隆汇3月8日丨归创通桥-B(02190.HK)发布公告,公司将于2024年3月21日(星期四)举行董事会会议,藉以(其中包括)审议及批准公司及其附属公司截至2023年12月31日止年度的年度业绩及其发布,以及处理其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030817021587649470&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030817021587649470&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zyloxmedical.com","stockEarnings":[{"period":"1week","weight":-0.0096},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1433},{"period":"6month","weight":-0.0894},{"period":"1year","weight":-0.2077},{"period":"ytd","weight":-0.2548}],"compareEarnings":[{"period":"1week","weight":-0.0298},{"period":"1month","weight":-0.0193},{"period":"3month","weight":0.0598},{"period":"6month","weight":-0.0552},{"period":"1year","weight":-0.2046},{"period":"ytd","weight":-0.0483}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"归创通桥医疗科技股份有限公司(原名:浙江归创医疗器械有限公司),是一家主要从事神经和外周血管介入医疗器械产品研发的中国公司。该公司主要产品包括蛟龙颅内取栓支架和Ultrafree药物洗脱PTA球囊扩张导管(Ultrafree DCB)。该公司产品销往国内外市场。","exchange":"SEHK","name":"归创通桥-B","nameEN":"ZYLOXTB-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"归创通桥-B(02190)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供归创通桥-B(02190)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"归创通桥-B,02190,归创通桥-B股票,归创通桥-B股票老虎,归创通桥-B股票老虎国际,归创通桥-B行情,归创通桥-B股票行情,归创通桥-B股价,归创通桥-B股市,归创通桥-B股票价格,归创通桥-B股票交易,归创通桥-B股票购买,归创通桥-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"归创通桥-B(02190)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供归创通桥-B(02190)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}